Medical liquid composition for aerial administration
US-2024358636-A1 · Oct 31, 2024 · US
US2018214556A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2018214556-A1 |
| Application number | US-201715694534-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 1, 2017 |
| Priority date | May 14, 2014 |
| Publication date | Aug 2, 2018 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a liquid composition which comprises, in an aqueous medium, one or more protein(s) and one or more solubilizing agent(s) chosen from the group consisting of anionic compounds of non-saccharide structure, said structure of which contains at least one aromatic nucleus comprising at least 6 ring members (6 atoms) and at least one carboxylic acid group in salified form, and which has, in its acid form, a molar mass of between 130 and 500 g/mol. It also relates to the use of said solubilizing agent(s) for preparing compositions according to the invention. It also relates to a process for solubilizing one or more protein(s), wherein at least one solubilizing agent chosen from the group consisting of anionic compounds of non-saccharide structure, said structure of which contains at least one aromatic nucleus comprising at least 6 ring members (6 atoms) and at least one carboxylic acid group in salified form, and which has, in its acid form, a molar mass of between 130 and 500 g/mol, is added to an aqueous protein preparation in order to solubilize the protein.
Opening claim text (preview).
What is claimed is: 1 . A process for solubilizing one or more protein(s) in water, wherein at least one solubilizing agent chosen from the group consisting of anionic compounds of non-saccharide structure, said structure of which contains at least one aromatic nucleus comprising at least 6 ring members (6 atoms) and at least one carboxylic acid group in salified form and which, in its acid form, has a molar mass of between 130 and 500 g/mol, is added to an aqueous protein composition. 2 . A process for solubilizing proteins within an aqueous composition, of at least one solubilizing agent chosen from the group consisting of anionic compounds of non-saccharide structure, said structure of which contains at least one aromatic nucleus comprising at least 6 ring members (6 atoms) and at least one carboxylic acid group in salified form, and which has, in its acid form, a molar mass of between 130 and 500 g/mol. 3 . The process for solubilizing agent(s) correspond(s) to general formula (I) below: with: Ar denoting an aromatic nucleus comprising at least 6 ring members; X denoting a saturated or unsaturated, linear or branched divalent radical, the main chain of which consists of 1 to 4 carbon atoms and optionally 1 or 2 heteroatoms chosen from nitrogen and oxygen atoms, it being possible for said main chain to optionally bear one or more substituents; Y1 and Y2 denoting, independently of one another: a hydrogen atom; an —OH group; an —OR1 group with R1 denoting an alkyl radical containing from 1 to 6 carbon atoms or a hydroxyalkyl radical containing from 1 to 6 carbon atoms; and preferably Y1 and Y2 denote, independently of one another, a hydrogen atom or an —OH group; and M denoting a cation. 4 . The process as claimed in claim 3 , wherein, in formula (I), Ar denotes a benzene nucleus or an indole nucleus. 5 . The process as claimed in claim 3 , wherein the solubilizing agent(s) correspond(s) to formula (Ia) below: with X, Y1, Y2 and M as defined in claim 3 . 6 . The process as claimed in claim 3 , wherein the solubilizing agent(s) correspond(s) to formula (Ib) below: with X, Y1, Y2 and M as defined in claim 3 . 7 . The process as claimed in claims 3 , wherein, in formula (I), (Ia) or (Ib), the divalent radical X bears, on its main chain, one or more substituents corresponding to the general formula: -L-Z with: L denotes a single bond or a group chosen from an amide group —NHCO—, a carbamate group —NHCOO— or a urea group —NHCONH—; and Z denotes a hydroxyl group (—OH); a saturated or unsaturated, linear or branched radical comprising from 1 to 4 carbon atoms, said carbon atoms bearing at least one hydroxyl group —[CH2]X-[OH]Y; a salified carboxylic acid group (—COOM′ with M′=Na+or K+); or a saturated or unsaturated, linear or branched radical comprising from 1 to 12 carbon atoms and optionally one or more heteroatoms. 8 . The process as claimed in claim 7 , wherein L denotes a single bond or an amide group. 9 . The process as claimed in claim 1 , wherein the solubilizing agent is resulting from a natural or synthetic amino acid bearing an aromatic ring, chosen from phenylalanine, tyrosine and tryptophan, and phenylalanine. 10 . The process as claimed in claim 1 , wherein the solubilizing agent is chosen from the group consisting of N-hydroxyacetylphenylalanine and N-hydroxyacetyltryptophan, corresponding to the formulae below: used in the form of a sodium salt or of a potassium salt. 11 . The process as claimed in claim 1 , wherein the solubilizing agent is resulting from a phenol. 12 . The process as claimed in claim 1 , wherein the solubilizing agent is chosen from the following compounds, used in the form of sodium salts or of potassium salts: Name Structure Phenylacetic acid Mandelic acid Hydrocinnamic acid Trans-cinnamic acid 2-Phenoxypropionic acid 3-Phenyllactic acid Phenylsuccinic acid Alpha-hydroxyhippuric acid 13 . The process as claimed in claim 1 , wherein said aqueous composition comprises the solubilizing agent(s) in a total concentration of between 1 g/l and 100 g/l. 14 . The process as claimed in claim 1 , wherein said aqueous composition contains a total concentration of protein(s) of between 0.5 and 400 mg/ml. 15 . The process as cl
Drugs for immunological or allergic disorders · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
from serum, plasma · CPC title
Amino acids, e.g. glycine, EDTA or aspartame · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.